COCP - Cocrystal Pharma Inc Stock Price, Fair Value and News

1.51USD-0.05 (-3.21%)Market Closed

Market Summary

USD1.51-0.05

Market Closed

-3.21%

COCP Stock Price

View Fullscreen

COCP RSI Chart

COCP Valuation

Market Cap

15.4M

Price/Earnings (Trailing)

-0.85

Price/Sales (Trailing)

7.22

EV/EBITDA

0.97

Price/Free Cashflow

-1.04

COCP Price/Sales (Trailing)

COCP Profitability

EBT Margin

-479.05%

Return on Equity

-68.16%

Return on Assets

-57.53%

Free Cashflow Yield

-96.23%

COCP Fundamentals

COCP Revenue

Revenue (TTM)

2.0M

COCP Earnings

Earnings (TTM)

-18.0M

Earnings Growth (Yr)

0.82%

Earnings Growth (Qtr)

-7.18%

Breaking Down COCP Revenue

Last 7 days

0.7%

Last 30 days

1.3%

Last 90 days

-4.4%

Trailing 12 Months

-38.4%

How does COCP drawdown profile look like?

COCP Financial Health

Current Ratio

8.92

Debt/Equity

0.08

Debt/Cashflow

-7.19

COCP Investor Care

Shares Dilution (1Y)

24.93%

Diluted EPS (TTM)

-1.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	1.9M	1.9M	1.9M	2.0M
2019	3.8M	4.7M	5.6M	6.6M
2018	0	0	2.0M	2.9M
2016	100.0K	112.0K	1.0M	0
2015	6.2M	4.1M	2.1M	78.0K
2014	0	0	0	8.2M
2013	15.9M	12.9M	10.3M	0
2012	13.5M	15.8M	16.6M	17.3M
2011	14.6M	14.0M	13.4M	12.8M
2010	0	0	0	15.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cocrystal Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2023	frost phillip md et al	bought	2,000,000	1.97	1,015,230	-
Aug 20, 2021	pfenniger richard c jr	bought	41,120	1.028	40,000	-
May 04, 2021	schinazi raymond f	sold	-1,696,250	2.95	-575,000	-
Oct 25, 2019	schinazi raymond f	bought	9,091	1.15	7,906	-
Oct 24, 2019	schinazi raymond f	bought	5,858	1.15	5,094	-
Oct 23, 2019	schinazi raymond f	bought	4,086	1.0386	3,935	-

Which funds bought or sold COCP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-40,742	474,735	-%
Mar 04, 2024	VIMA LLC	new	-	387	387	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-4,155	41,553	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.54	-1,420	15,462	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-52.14	-76,250	58,725	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	74.55	3,802	10,063	-%
Feb 13, 2024	MORGAN STANLEY	added	33.35	18,960	102,087	-%
Feb 13, 2024	NORTHERN TRUST CORP	unchanged	-	-1,805	21,023	-%
Feb 13, 2024	FMR LLC	reduced	-97.86	-343	7.00	-%

Are Funds Buying or Selling COCP?

Are funds buying COCP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own COCP

No. of Funds

Unveiling Cocrystal Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	sabby management, llc	12.%	0	SC 13G/A
Apr 14, 2023	frost phillip md et al	13.1%	1,332,608	SC 13D/A
Apr 12, 2023	hassan fred	10.0%	1,015,229	SC 13G
Jan 10, 2023	sabby management, llc	5.17%	420,710	SC 13G/A
Jan 04, 2022	sabby management, llc	5.89%	5,738,120	SC 13G/A
Jun 10, 2021	frost phillip md et al	3.8%	3,726,306	SC 13D/A
May 25, 2021	fivet investment management ltd	0.00%	0	SC 13D
May 17, 2021	ayrton capital llc	6.69%	6,520,000	SC 13G
May 12, 2021	sabby management, llc	9.99%	9,740,000	SC 13G
Feb 16, 2021	cvi investments, inc.	-	0	SC 13G/A

Recent SEC filings of Cocrystal Pharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	10-K/A	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report

Peers (Alternatives to Cocrystal Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Cocrystal Pharma Inc News

Latest updates

Cocrystal Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2013Q3	2013Q2	2013Q1
Revenue	4.3%	510,000	489,000	554,000	461,000	402,000	492,000	592,000	5,078,000	3,818,250	2,558,500	1,298,750	39,000	49,000	-	24,000	27,000	713,662	1,400,324	2,086,986	1,955,982	2,028,897
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,109,821	551,698	592,083
Operating Expenses	-38.2%	1,976,000	3,198,000	4,004,000	2,422,000	48,327,000	2,300,000	2,142,000	2,201,000	56,304,500	2,419,000	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	14.0%	1,278,000	1,121,000	2,028,000	1,139,000	1,266,000	1,223,000	1,051,000	1,323,000	1,196,000	952,000	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-66.4%	698,000	2,077,000	1,976,000	1,283,000	958,000	1,077,000	1,091,000	878,000	1,203,500	1,467,000	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-Infinity%	-4.71	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	2,000	2,000	2,000	2,000	9,000	5,000	5,000	-6,000	-3,000	500	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-12,124,500	-483,000	-	-	-	15,300,000	-	-52,000	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-47,845,000	-1,780,000	-1,515,000	2,971,000	-56,409,500	-2,351,000	-1,881,000	-3,227,000	-	-	-	-	-	-	-6,058,242	-	-
EBT Margin	-Infinity%	-4.79	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	44.1%	-1,493,000	-2,670,000	-3,495,000	-1,990,000	-47,845,000	-1,780,000	-1,515,000	2,971,000	-44,286,000	-1,868,000	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-Infinity%	-4.79	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-2,382,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.2%	31.00	33.00	36.00	38.00	41.00	46.00	52.00	75.00	79.00	83.00	87.00	54.00	54.00	53.00	40.00	43.00	29.00	73.00	75.00	76.00	69.00
Current Assets	-9.7%	29.00	32.00	36.00	37.00	40.00	45.00	52.00	55.00	59.00	62.00	67.00	34.00	34.00	33.00	20.00	23.00	8.00	7.00	9.00	10.00	3.00
Cash Equivalents	-11.4%	26.00	30.00	32.00	34.00	37.00	42.00	51.00	55.00	59.00	62.00	67.00	33.00	33.00	32.00	19.00	22.00	7.00	6.00	7.00	9.00	3.00
Net PPE	7.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	-	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	65.00	65.00	65.00	65.00
Liabilities	153.4%	5.00	2.00	2.00	3.00	1.00	2.00	3.00	2.00	2.00	2.00	3.00	2.00	2.00	3.00	3.00	2.00	3.00	3.00	2.00	2.00	2.00
Current Liabilities	69.5%	3.00	2.00	2.00	3.00	1.00	2.00	3.00	2.00	2.00	1.00	2.00	1.00	1.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	-14.0%	26.00	31.00	0.00	35.00	40.00	50.00	49.00	74.00	78.00	81.00	85.00	52.00	53.00	50.00	37.00	40.00	26.00	71.00	72.00	74.00	67.00
Retained Earnings	-1.4%	-315	-311	-307	-303	-297	-293	-287	-263	-259	-255	-251	-247	-244	-243	-240	-237	-235	-187	-185	-184	-187
Additional Paid-In Capital	0.0%	342	342	342	338	337	337	337	337	337	336	336	300	297	294	278	278	261	258	258	258	254
Shares Outstanding	0%	10.00	10.00	10.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	6.00	6.00	-	-	-	-	-	-	-	-
Float	-	-	-	19.00	-	-	-	38.00	-	-	-	116	-	-	-	64.00	-	-	-	38,555	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-24.1%	-3,326	-2,681	-5,548	-3,111	-4,893	-8,908	-3,724	-3,910	-2,922	-5,403	-2,624	-1,770	-2,381	-3,061	-2,200	-2,188	-1,230	-1,323	-1,028	2,018	-1,970
Share Based Compensation	-8.7%	158	173	179	291	159	216	241	239	222	205	78.00	219	199	237	119	107	138	108	33.00	33.00	231
Cashflow From Investing	-Infinity%	-59.00	-	-14.00	-45.00	-12.00	-	-	-	-8.00	-4.00	-15.00	-25.00	-1.00	-19.00	-127	-93.00	-1.00	-115	-4.00	-25.00	-15.00
Cashflow From Financing	-	-	-	4,000	-7.00	-7.00	-7.00	-7.00	-6.00	-9.00	-11.00	36,423	2,063	3,611	15,546	-44.00	16,549	2,655	-42.00	-65.00	3,876	24.00

COCP Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 15,169	$ 12,392
General and administrative	5,990	5,745
Legal settlement	(2,600)	1,600
Impairments		19,092
Total operating expenses	18,559	38,829
Loss from operations	(18,559)	(38,829)
Other (expense) income:
Interest income (expense), net	640	(2)
Change in fair value of derivative liabilities		12
Foreign exchange loss	(65)	(18)
Total other income (expense), net	575	(8)
Net loss	$ (17,984)	$ (38,837)
Net loss per common share:
Net loss per common share, basic	$ (1.87)	$ (4.77)
Net loss per common share, diluted	$ (1.87)	$ (4.77)
Weighted average number of common shares, basic	9,651	8,143
Weighted average number of common shares, diluted	9,651	8,143

COCP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 26,353	$ 37,144
Restricted cash	75	75
Tax credit receivable	890	716
Prepaid expenses and other current assets	1,773	2,243
Total current assets	29,091	40,178
Property and equipment, net	271	342
Deposits	46	46
Operating lease right-of-use assets, net (including $42 and $99 to related party)	1,851	274
Total assets	31,259	40,840
Current liabilities:
Accounts payable and accrued expenses	3,022	976
Current maturities of finance lease liabilities		7
Current maturities of operating lease liabilities (including $42 and $59 to related party)	240	233
Total current liabilities	3,262	1,216
Long-term liabilities:
Operating lease liabilities (including $0 and $42 to related party)	1,613	57
Total long-term liabilities	1,613	57
Total liabilities	4,875	1,273
Commitments and contingencies
Stockholders’ equity:
Common stock $0.001 par value; 150,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 10,174 and 8,143 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	10	8
Additional paid-in capital	342,288	337,489
Accumulated deficit	(315,914)	(297,930)
Total stockholders’ equity	26,384	39,567
Total liabilities and stockholders’ equity	$ 31,259	$ 40,840

About Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

CEO	Dr. Sam Lee Ph.D.
WEBSITE	cocrystalpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Cocrystal Pharma Inc Frequently Asked Questions

What is the ticker symbol for Cocrystal Pharma Inc? What does COCP stand for in stocks?

COCP is the stock ticker symbol of Cocrystal Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cocrystal Pharma Inc (COCP)?

As of Thu Apr 25 2024, market cap of Cocrystal Pharma Inc is 15.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COCP stock?

You can check COCP's fair value in chart for subscribers.

What is the fair value of COCP stock?

You can check COCP's fair value in chart for subscribers. The fair value of Cocrystal Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cocrystal Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COCP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cocrystal Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether COCP is over valued or under valued. Whether Cocrystal Pharma Inc is cheap or expensive depends on the assumptions which impact Cocrystal Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COCP.

What is Cocrystal Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, COCP's PE ratio (Price to Earnings) is -0.85 and Price to Sales (PS) ratio is 7.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COCP PE ratio will change depending on the future growth rate expectations of investors.